Several drug programs aim to restore the balance between regulatory T cells and T helper 17 (Th17) cells in autoimmune disease. But as therapies advance in the clinic, new discoveries are challenging the fundamental principle that T-cell lineages, once established, don't change. Ken Garber reports.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Ingrid McNamara
References
Dardalhon, V. et al. Nat. Immunol. 9, 1347–1355 (2008).
Putnam, A.L. et al. Diabetes 58, 652–662 (2009).
Duerr, R.H. et al. Science 314, 1461–1463 (2006).
Schmidt, C. Nat. Biotechnol. 26, 1317–1318 (2008).
Xu, L. et al. J. Immunol. 178, 6725–6729 (2007).
Shi, G. et al. J. Immunol. 181, 7205–7213 (2008).
Lee, Y.K. et al. Immunity 30, 92–107 (2009).
Wei, G. et al. Immunity 30, 155–167 (2009).
Beriou G. et al. Blood 113, 4240–4249 (2009).
Segal, B.M. et al. Lancet Neurol. 7, 796–804 (2008).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. Immunology's quiet upheaval. Nat Biotechnol 27, 687–689 (2009). https://doi.org/10.1038/nbt0809-687
Issue Date:
DOI: https://doi.org/10.1038/nbt0809-687
